Once-weekly semaglutide demonstrated consistent bl

Orlando, US, 3 April 2017 - Findings from a post hoc analysis of the phase 3a SUSTAIN 2-4 trials demonstrated greater mean reductions in HbA _1c and body weight with once-weekly semaglutide treatment compared to sitagliptin, exenatide extended release (ER) and insulin glargine U100 in adults with type 2 diabetes, across multiple background oral antidiabetic (OAD) treatment categories. The results were presented at the Endocrine Society's 99 ^th Annual Meeting and Expo (ENDO 2017) in Orlando, FL, US. ¹

"Type 2 diabetes is a complex disease, and as a result many patients are not reaching their targets on current oral antidiabetic therapy," said Vanita Aroda, SUSTAIN 4 investigator and physician investigator at the MedStar Health Research Institute, Hyattsville, MD, US. "Results from this post hoc analysis show that once-weekly semaglutide consistently lowered blood glucose and weight in people with type 2 diabetes regardless of their current oral antidiabetic therapy."  

Read the full release including references

Further information

http://www.globenewswire.com/NewsRoom/Attachm...92c7a18377